BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Latchaw RE, Albers SL. Imaging the Cervical Vasculature. Progress in Cardiovascular Diseases 2017;59:555-84. [DOI: 10.1016/j.pcad.2017.05.007] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Tsushima Y, Ishiguchi T, Murakami T, Hayashi H, Hayakawa K, Fukuda K, Korogi Y, Sugimoto H, Takehara Y, Narumi Y, Arai Y, Kuwatsuru R, Yoshimitsu K, Awai K, Kanematsu M, Takagi R. Safe use of iodinated and gadolinium-based contrast media in current practice in Japan: a questionnaire survey. Jpn J Radiol 2016;34:130-9. [DOI: 10.1007/s11604-015-0505-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
3 Elbeshlawi I, Abdelbaki MS. Safety of Gadolinium Administration in Children. Pediatric Neurology 2018;86:27-32. [DOI: 10.1016/j.pediatrneurol.2018.07.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
4 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bai J, Wang X, Zhang C, Huang J, Müller WEG. Lanthanum-containing bioparticles are associated with the influence of lanthanum on high phosphate mediated bone marrow stromal cells viability. Biometals 2018;31:771-84. [DOI: 10.1007/s10534-018-0121-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Turyanskaya A, Rauwolf M, Pichler V, Simon R, Burghammer M, Fox OJL, Sawhney K, Hofstaetter JG, Roschger A, Roschger P, Wobrauschek P, Streli C. Detection and imaging of gadolinium accumulation in human bone tissue by micro- and submicro-XRF. Sci Rep 2020;10:6301. [PMID: 32286449 DOI: 10.1038/s41598-020-63325-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
7 Beydemir Ş, Türkeş C, Yalçın A. Gadolinium-based contrast agents: in vitro paraoxonase 1 inhibition, in silico studies. Drug Chem Toxicol 2021;44:508-17. [PMID: 31179770 DOI: 10.1080/01480545.2019.1620266] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
8 Nardo L, Abdelhafez YG, Acquafredda F, Schirò S, Wong AL, Sarohia D, Maroldi R, Darrow MA, Guindani M, Lee S, Zhang M, Moawad AW, Elsayes KM, Badawi RD, Link TM. Qualitative evaluation of MRI features of lipoma and atypical lipomatous tumor: results from a multicenter study. Skeletal Radiol 2020;49:1005-14. [PMID: 31965239 DOI: 10.1007/s00256-020-03372-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
9 Barbieri S, Schroeder C, Froehlich JM, Pasch A, Thoeny HC. High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification. Contrast Media Mol Imaging 2016;11:245-50. [PMID: 26929131 DOI: 10.1002/cmmi.1683] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
10 Anemone A, Consolino L, Longo DL. MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent. Eur Radiol 2017;27:2170-9. [DOI: 10.1007/s00330-016-4552-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
11 Rasschaert M, Emerit A, Fretellier N, Factor C, Robert P, Idée JM, Corot C. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats. Invest Radiol 2018;53:328-37. [PMID: 29329151 DOI: 10.1097/RLI.0000000000000447] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
12 Frenzel T, Apte C, Jost G, Schöckel L, Lohrke J, Pietsch H. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. Invest Radiol 2017;52:396-404. [PMID: 28125438 DOI: 10.1097/RLI.0000000000000352] [Cited by in Crossref: 141] [Cited by in F6Publishing: 48] [Article Influence: 35.3] [Reference Citation Analysis]
13 Wáng YX, Schroeder J, Siegmund H, Idée JM, Fretellier N, Jestin-Mayer G, Factor C, Deng M, Kang W, Morcos SK. Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats. Quant Imaging Med Surg 2015;5:534-45. [PMID: 26435917 DOI: 10.3978/j.issn.2223-4292.2015.05.03] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
14 Garcia J, Liu SZ, Louie AY. Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus. Philos Trans A Math Phys Eng Sci 2017;375:20170180. [PMID: 29038383 DOI: 10.1098/rsta.2017.0180] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
15 Boehm-sturm P, Haeckel A, Hauptmann R, Mueller S, Kuhl CK, Schellenberger EA. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging. Radiology 2018;286:537-46. [DOI: 10.1148/radiol.2017170116] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
16 Feng M, Fan YZ, Ma XJ, Li JX, Yang XG. The gadolinium-based contrast agent Omniscan® promotes in vitro fibroblast survival through in situ precipitation. Metallomics 2015;7:1103-10. [PMID: 25867453 DOI: 10.1039/c5mt00055f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Idée J, Fretellier N, Thurnher M, Bonnemain B, Corot C. Physico-chimie et profil toxicologique d’agents de contraste pour l’imagerie par résonance magnétique, les chélates de gadolinium. Annales Pharmaceutiques Françaises 2015;73:266-76. [DOI: 10.1016/j.pharma.2015.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
18 Taghipour M, Ziaei A, Alessandrino F, Hassanzadeh E, Harisinghani M, Vangel M, Tempany CM, Fennessy FM. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdom Radiol (NY) 2019;44:1520-7. [PMID: 30361870 DOI: 10.1007/s00261-018-1807-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
19 Rowe PS, Zelenchuk LV, Laurence JS, Lee P, Brooks WM, McCarthy ET. Do ASARM peptides play a role in nephrogenic systemic fibrosis? Am J Physiol Renal Physiol 2015;309:F764-9. [PMID: 26336161 DOI: 10.1152/ajprenal.00201.2015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
20 Slabu I, Wiemer K, Steitz J, Liffmann R, Mues B, Eisold S, Caumanns T, Mayer J, Kuhl CK, Schmitz-rode T, Simon U. Size-Tailored Biocompatible FePt Nanoparticles for Dual T1 / T2 Magnetic Resonance Imaging Contrast Enhancement. Langmuir 2019;35:10424-34. [DOI: 10.1021/acs.langmuir.9b00337] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
21 Chehabeddine L, Al Saleh T, Baalbaki M, Saleh E, Khoury SJ, Hannoun S. Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents. Critical Reviews in Toxicology 2019;49:262-79. [DOI: 10.1080/10408444.2019.1592109] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
22 Chen K, Li P, Zhu C, Xia Z, Xia Q, Zhong L, Xiao B, Cheng T, Wu C, Shen C, Zhang X, Zhu J. Mn(II) Complex of Lipophilic Group-Modified Ethylenediaminetetraacetic Acid (EDTA) as a New Hepatobiliary MRI Contrast Agent. J Med Chem 2021;64:9182-92. [PMID: 34152137 DOI: 10.1021/acs.jmedchem.1c00393] [Reference Citation Analysis]
23 Knoepp F, Bettmer J, Fronius M. Gadolinium released by the linear gadolinium-based contrast-agent Gd-DTPA decreases the activity of human epithelial Na+ channels (ENaCs). Biochim Biophys Acta Biomembr 2017;1859:1040-8. [PMID: 28257815 DOI: 10.1016/j.bbamem.2017.02.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
24 Gao S, George SJ, Zhou Z. Interaction of Gd-DTPA with phosphate and phosphite: toward the reaction intermediate in nephrogenic systemic fibrosis. Dalton Trans 2016;45:5388-94. [DOI: 10.1039/c5dt04172d] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
25 Rai DB, Gupta N, Pooja D, Kulhari H. Dendrimers for diagnostic applications. Pharmaceutical Applications of Dendrimers. Elsevier; 2020. pp. 291-324. [DOI: 10.1016/b978-0-12-814527-2.00013-5] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Mekuria SL, Debele TA, Tsai H. PAMAM dendrimer based targeted nano-carrier for bio-imaging and therapeutic agents. RSC Adv 2016;6:63761-72. [DOI: 10.1039/c6ra12895e] [Cited by in Crossref: 26] [Article Influence: 4.3] [Reference Citation Analysis]
27 Beomonte Zobel B, Quattrocchi CC, Errante Y, Grasso RF. Gadolinium-based contrast agents: did we miss something in the last 25 years? Radiol Med 2016;121:478-81. [PMID: 26706453 DOI: 10.1007/s11547-015-0614-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
28 Nörenberg D, Schmidt F, Schinke K, Frenzel T, Pietsch H, Giese A, Ertl-Wagner B, Levin J. Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. PLoS One 2020;15:e0231495. [PMID: 32324769 DOI: 10.1371/journal.pone.0231495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Sim N, Parker D. Critical design issues in the targeted molecular imaging of cell surface receptors. Chem Soc Rev 2015;44:2122-34. [DOI: 10.1039/c4cs00364k] [Cited by in Crossref: 28] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
30 Ayat NR, Qin JC, Cheng H, Roelle S, Gao S, Li Y, Lu ZR. Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI. ACS Med Chem Lett 2018;9:730-5. [PMID: 30034609 DOI: 10.1021/acsmedchemlett.8b00172] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
31 Robic C, Port M, Rousseaux O, Louguet S, Fretellier N, Catoen S, Factor C, Le Greneur S, Medina C, Bourrinet P, Raynal I, Idée JM, Corot C. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol 2019;54:475-84. [PMID: 30973459 DOI: 10.1097/RLI.0000000000000563] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 8.5] [Reference Citation Analysis]
32 Pallares RM, An DD, Hébert S, Faulkner D, Loguinov A, Proctor M, Villalobos JA, Bjornstad KA, Rosen CJ, Vulpe C, Abergel RJ. Delineating toxicity mechanisms associated with MRI contrast enhancement through a multidimensional toxicogenomic profiling of gadolinium. Mol Omics 2022. [PMID: 35040455 DOI: 10.1039/d1mo00267h] [Reference Citation Analysis]
33 Robert P, Frenzel T, Factor C, Jost G, Rasschaert M, Schuetz G, Fretellier N, Boyken J, Idée JM, Pietsch H. Methodological Aspects for Preclinical Evaluation of Gadolinium Presence in Brain Tissue: Critical Appraisal and Suggestions for Harmonization-A Joint Initiative. Invest Radiol 2018;53:499-517. [PMID: 29659381 DOI: 10.1097/RLI.0000000000000467] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
34 Dekkers IA, Roos R, van der Molen AJ. Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol 2018;28:1579-84. [DOI: 10.1007/s00330-017-5065-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
35 Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ 2nd, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. AJR Am J Roentgenol. 2015;205:469-478. [PMID: 26295633 DOI: 10.2214/ajr.14.14268] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
36 Prybylski JP, Jay M. The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis. Adv Chronic Kidney Dis 2017;24:176-82. [PMID: 28501081 DOI: 10.1053/j.ackd.2017.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
37 Thomsen HS. Generic gadolinium-based contrast agents: the future? Acta Radiol 2017;58:1285-7. [PMID: 28691527 DOI: 10.1177/0284185117719576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Osterode W, Falkenberg G, Regele H. Gadolinium distribution in kidney tissue determined and quantified by micro synchrotron X-ray fluorescence. Biometals 2021;34:341-50. [PMID: 33486677 DOI: 10.1007/s10534-020-00284-8] [Reference Citation Analysis]
39 Mekuria SL, Debele TA, Tsai H. Encapsulation of Gadolinium Oxide Nanoparticle (Gd 2 O 3 ) Contrasting Agents in PAMAM Dendrimer Templates for Enhanced Magnetic Resonance Imaging in Vivo. ACS Appl Mater Interfaces 2017;9:6782-95. [DOI: 10.1021/acsami.6b14075] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
40 Bower DV, Richter JK, von Tengg-kobligk H, Heverhagen JT, Runge VM. Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases With Reduced Kinetic Stability of the Agent: . Investigative Radiology 2019;54:453-63. [DOI: 10.1097/rli.0000000000000567] [Cited by in Crossref: 31] [Cited by in F6Publishing: 4] [Article Influence: 10.3] [Reference Citation Analysis]
41 Werner P, Taupitz M, Schröder L, Schuenke P. An NMR relaxometry approach for quantitative investigation of the transchelation of gadolinium ions from GBCAs to a competing macromolecular chelator. Sci Rep 2021;11:21731. [PMID: 34741037 DOI: 10.1038/s41598-021-00974-4] [Reference Citation Analysis]
42 Baek AR, Kim H, Park S, Lee GH, Kang HJ, Jung J, Park J, Ryeom H, Kim T, Chang Y. Gadolinium Complex of 1,4,7,10-Tetraazacyclododecane-1,4,7-trisacetic Acid (DO3A)–Ethoxybenzyl (EOB) Conjugate as a New Macrocyclic Hepatobiliary MRI Contrast Agent. J Med Chem 2017;60:4861-8. [DOI: 10.1021/acs.jmedchem.7b00060] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
43 Le Fur M, Caravan P. The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists. Metallomics 2019;11:240-54. [PMID: 30516229 DOI: 10.1039/c8mt00302e] [Cited by in Crossref: 55] [Cited by in F6Publishing: 17] [Article Influence: 27.5] [Reference Citation Analysis]
44 Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016;29:365-76. [PMID: 27053146 DOI: 10.1007/s10534-016-9931-7] [Cited by in Crossref: 336] [Cited by in F6Publishing: 265] [Article Influence: 56.0] [Reference Citation Analysis]
45 Fan B, Li M, Wang X, Xu Y, Li F, Zhang L, Jiang J, Jiang Y. Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases. J Magn Reson Imaging 2017;45:1827-34. [PMID: 27696616 DOI: 10.1002/jmri.25491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Han Z, Wu X, Roelle S, Chen C, Schiemann WP, Lu ZR. Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer. Nat Commun 2017;8:692. [PMID: 28947734 DOI: 10.1038/s41467-017-00741-y] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
47 Strzeminska I, Factor C, Robert P, Grindel AL, Comby PO, Szpunar J, Corot C, Lobinski R. Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents. Invest Radiol 2020;55:138-43. [PMID: 31917763 DOI: 10.1097/RLI.0000000000000623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
48 Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J, Fredrikson S, Kristoffersen-Wiberg M, Granberg T. Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study. AJNR Am J Neuroradiol 2017;38:1311-6. [PMID: 28495943 DOI: 10.3174/ajnr.A5211] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 7.2] [Reference Citation Analysis]
49 Runge VM. Dechelation (Transmetalation): Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast Agents, In View of Recent Health Care Rulings by the EMA (Europe), FDA (United States), and PMDA (Japan). Invest Radiol 2018;53:571-8. [PMID: 30130320 DOI: 10.1097/RLI.0000000000000507] [Cited by in Crossref: 34] [Cited by in F6Publishing: 3] [Article Influence: 11.3] [Reference Citation Analysis]
50 Wang B, Gao J, Zhang Q, Zhang C, Liu G, Wei W, Huang H, Fu Y, Li D, Zhang B, Guo H. Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer. Abdom Radiol (NY) 2020;45:547-55. [PMID: 31907568 DOI: 10.1007/s00261-019-02281-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]